Boston Trust Walden Corp Lowers Holdings in Pfizer Inc. (NYSE:PFE)

Boston Trust Walden Corp trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 4.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,399 shares of the biopharmaceutical company’s stock after selling 3,751 shares during the period. Boston Trust Walden Corp’s holdings in Pfizer were worth $2,315,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in the business. Worth Asset Management LLC bought a new stake in shares of Pfizer in the first quarter worth about $29,000. Briaud Financial Planning Inc bought a new stake in shares of Pfizer in the third quarter worth about $30,000. GoalVest Advisory LLC increased its holdings in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. bought a new stake in shares of Pfizer in the third quarter worth about $34,000. Finally, VisionPoint Advisory Group LLC increased its holdings in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.0 %

Shares of NYSE:PFE opened at $26.66 on Friday. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $42.10. The business has a 50 day simple moving average of $27.37 and a two-hundred day simple moving average of $29.22. The firm has a market capitalization of $150.96 billion, a PE ratio of 74.06, a price-to-earnings-growth ratio of 1.19 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the previous year, the business earned $1.14 earnings per share. The company’s revenue for the quarter was down 41.3% compared to the same quarter last year. On average, equities analysts predict that Pfizer Inc. will post 2.22 EPS for the current year.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research reports. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Truist Financial reduced their price objective on Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday, April 1st. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.